Fibroblast activation protein and its prognostic significance in correlation with vascular endothelial growth factor in pancreatic adenocarcinoma

Molecular Medicine Reports

Volumn 11, Issue 6, 2015, Pages 4585-4590

  Patsouras, Dimitrios ^a   Papaxoinis, Kostis ^b   Kostakis, Alkiviadis ^c   Safioleas, Michael C ^b   Lazaris, Andreas C ^b   Nicolopoulou Stamati, Polyxeni ^b  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c BIOMEDICAL RESEARCH FOUNDATION   (Greece)

Author keywords

Fibroblast activation protein; Immunohistochemistry; Pancreatic cancer; Vascular endothelial growth factor

Indexed keywords

AMMONIUM CHLORIDE; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE KINASE; CYTOCHROME C; ETHYLENE GLYCOL 1,2 BIS(2 AMINOPHENYL) ETHER N,N,N',N' TETRAACETIC ACID; MESSENGER RNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; GELATINASE; MEMBRANE PROTEIN; SEPRASE; SERINE PROTEINASE; TUMOR MARKER; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL ISOLATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GROWTH INHIBITION; HYPERAMMONEMIA; LIVER CELL; LIVER CELL CULTURE; LIVER CELL DAMAGE; LIVER FAILURE; MTT ASSAY; NONHUMAN; PROTEIN EXPRESSION; RAT; SPRAGUE DAWLEY RAT; WESTERN BLOTTING; ADENOCARCINOMA; AGED; CANCER STAGING; CONFOCAL MICROSCOPY; FLUORESCENT ANTIBODY TECHNIQUE; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LYMPH NODE; MALE; METABOLISM; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PANCREAS TUMOR; PATHOLOGY; PROGNOSIS; VERY ELDERLY;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GELATINASES; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LYMPH NODES; MALE; MEMBRANE PROTEINS; MICROSCOPY, CONFOCAL; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PROGNOSIS; SERINE ENDOPEPTIDASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84924655616     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2015.3259     Document Type: Article

References (43)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clinic 63: 11-30, 2013.
2. Crist DW and Cameron JL: The current status of the Whipple operation for periampullary carcinoma. Adv Surg 25: 21-49, 1992.
3. Sohn TA, Yeo CJ, Cameron JL, et al: Resected adenocarcinoma of the pancreas-616 patients: results, outcomes and prognostic indicators. J Gastrointest Surg 4: 567-579, 2000.
4. Cleary SP, Gryfe R, Guindi M, et al: Prognostic factors in resected pancreatic adenocarcinoma: analysis of actual 5-year survivors. J Am Coll Surg 198: 722-731, 2004.
5. Han SS, Jang JY, Kim SW, Kim WH, Lee KU and Park YH: Analysis of long-term survivors after surgical resection for pancreatic cancer. Pancreas 32: 271-275, 2006.
6. Moon HJ, An JY, Heo JS, Choi SH, Joh JW and Kim YI: Predicting survival after surgical resection for pancreatic ductal adenocarcinoma. Pancreas 32: 37-43, 2006.
7. Matsuno S, Egawa S, Fukuyama S, et al: Pancreatic cancer registry in Japan: 20 years of experience. Pancreas 28: 219-230, 2004.
8. Whitehurst B, Flister MJ, Bagaitkar J, et al: Anti-VEGF-A therapy reduces lymphatic vessel density and expression of VEGFR-3 in an orthotopic breast tumor model. Int J Cancer 121: 2181-2191, 2007.
9. Christiansen A and Detmar M: Lymphangiogenesis and cancer. Genes Cancer 2: 1146-1158, 2011.
10. Shinkaruk S, Bayle M, Laïn G and Déléris G: Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy. Curr Med Chem Anticancer Agents 3: 95-117, 2003.
11. Brown LF, Guidi AJ, Schnitt SJ, et al: Vascular stroma formation in carcinoma in situ, invasive carcinoma and metastatic carcinoma of the breast. Clin Cancer Res 5: 1041-1056, 1999.
12. Fukumura D, Xavier R, Sugiura T, et al: Tumor induction of VEGF promoter activity in stromal cells. Cell 94: 715-725, 1998.
13. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS and Dvorak HF: Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219: 983-985, 1983.
14. Dvorak HF, Sioussat TM, Brown LF, et al: Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: concentration in tumor blood vessels. J Exp Med 174: 1275-1278, 1991.
15. Feng D, Nagy JA, Brekken RA, et al: Ultrastructural localization of the vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) receptor-2 (FLK-1, KDR) in normal mouse kidney and in the hyperpermeable vessels induced by VPF/VEGF-expressing tumors and adenoviral vectors. J Histochem Cytochem 48: 545-556, 2000.
16. Leung DW, Cachianes G, Kuang WJ, Goeddel DV and Ferrara N: Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246: 1306-1309, 1989.
17. Mahadevan D and Von Hoff DD: Tumor-stroma interactions in pancreatic ductal adenocarcinoma. Mol Cancer Ther 6: 1186-1197, 2007.
18. Ikeda N, Adachi M, Taki T, et al: Prognostic significance of angiogenesis in human pancreatic cancer. Br J Cancer 79: 1553-1563, 1999.
19. Itakura J, Ishiwata T, Shen B, Kornmann M and Korc M: Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer. Int J Cancer 85: 27-34, 2000.
20. Fujimoto K, Hosotani R, Wada M, et al: Expression of two angiogenic factors, vascular endothelial growth factor and platelet-derived endothelial cell growth factor in human pancreatic cancer and its relationship to angiogenesis. Eur J Cancer 34: 1439-1447, 1998.
21. Park JE, Lenter MC, Zimmermann RN, Garin-Chesa P, Old LJ and Rettig WJ: Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts. J Biol Chem 274: 36505-36512, 1999.
22. Garin-Chesa P, Old LJ and Rettig WJ: Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc Nat Acad Sci USA 87: 7235-7239, 1990.
23. Scanlan MJ, Raj BK, Calvo B, et al: Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers. Proc Nat Acad Sci USA 91: 5657-5661, 1994.
24. Mueller MM and Fusenig NE: Tumor-stroma interactions directing phenotype and progression of epithelial skin tumor cells. Differentiation 70: 486-497 2002.
25. Liotta LA, Steeg PS and Stetler-Stevenson WG: Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64: 327-336, 1991.
26. Cohen SJ, Alpaugh RK, Palazzo I, et al: Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinoma. Pancreas 37: 154-158, 2008.
27. Goscinski MA, Suo Z, Florenes VA, Vlatkovic L, Nesland JM and Giercksky KE: FAP-alpha and uPA show different expression patterns in premalignant and malignant esophageal lesions. Ultrastruct Pathol 32: 89-96, 2008.
28. Henry LR, Lee HO, Lee JS, et al: Clinical implications of fibroblast activation protein in patients with colon cancer. Clin Cancer Res 13: 1736-1741, 2007.
29. Földes-Papp Z, Demel U and Tilz GP: Laser scanning confocal fluorescence microscopy: an overview. Int Immunopharmacol 3: 1715-1729, 2003.
30. Amos WB andWhite JG: How the confocal laser scanning microscope entered biological research. Biol Cell 95: 335-342, 2003.
31. Papaxoinis K, Patsouris E, Kittas C and Nicolopoulou-Stamati P: Insulinlike growth factor I receptor and estrogen receptor beta expressions are inversely correlated in colorectal neoplasms and affected by the insulin resistance syndrome. Hum Pathol 38: 1037-1046, 2007.
32. Mason DY, Micklem K and Jones M: Double immunofluorescence labelling of routinely processed paraffin sections. J Pathol 191:452-461, 2000.
33. Hamilton SR and Aaltonen LA: Pathology and Genetics of Tumours of the Digestive System. In: World Health Organization Classification of Tumours. Kleihues P and Sobin LH (eds): IARC Press, Lyon, pp1-250, 2000.
34. Giulianotti PC, Boggi U, Fornaciari G, et al: Prognostic value of histological grading in ductal adenocarcinoma of the pancreas. Klöppel vs TNM grading. Int J Pancreatol 17: 279-289, 1995.
35. Edge SB, Byrd DR, Compton CC, et al (eds): AJCC Cancer Staging Manual. 7th edition. Springer, New York, NY, pp241-249, 2010.
36. Kraman M, Bambrough PJ, Arnold JN, et al: Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science 330: 827-830, 2010.
37. Shi M, Yu DH, Chen Y, et al: Expression of fibroblast activation protein in human pancreatic adenocarcinoma and its clinicopathological significance. World J Gastroenterol 18: 840-846, 2012.
38. Smith RA, Tang J, Tudur-Smith C, Neoptolemos JP and Ghaneh P: Meta-analysis of immunohistochemical prognostic markers in resected pancreatic cancer. Br J Cancer 104: 1440-1451, 2011.
39. Kindler HL, Ioka T, Richel DJ, et al: Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. Lancet Oncol 12: 256-262, 2011.
40. Spano JP, Chodkiewicz C, Maurel J, et al: Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study. Lancet 371: 2101-2108, 2008.
41. Cirri P and Chiarugi P: Cancer associated fibroblasts: the dark side of the coin. Am J Cancer Res 1: 482-497, 2011.
42. Rettig WJ, Garin-Chesa P, Healey JH, et al: Regulation and heteromeric structure of the fibroblast activation protein in normal and transformed cells of mesenchymal and neuroectodermal origin. Cancer Res 53: 3327-3335, 1993.
43. Crawford Y, Kasman I, Yu L, et al: PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell 15: 21-34, 2009.